Chiome Bioscience and Chugai Pharmaceutical Announce Research Agreement
News Jan 09, 2009
Chiome Bioscience and Chugai Pharmaceutical Co., Ltd. have signed a joint research agreement for the generation of monoclonal antibodies against multiple target proteins chosen by Chugai Pharmaceutical.
Chiome and Chugai will develop value-added therapeutic monoclonal antibodies employing Chiome’s ADLib® (Autonomously Diversifying Library) System and will apply the System to assessment of target proteins and lead generation of products for clinical use.
Chugai will pay a contractual up-front fee to Chiome and will also pay milestones based on the results of the research. Other contractual conditions were not disclosed. Chiome and Chugai had earlier established a research collaboration agreement in July 2007. This new agreement expands the number of the targets to be addressed and extends the term of the collaboration.
It is well known that exposure to daylight keeps our body clock in check. But what impact does meal timing have? A new study published in Cell helps answer this question and provides new insights on how cells keep a circadian rhythm. The study also has important implications for shift workers and travelers wanting to avoid jet lag.READ MORE